|
1
|
Ambrosini G, Adida C and Altieri DC: A
novel anti-apoptosis gene, survivin, expressed in cancer and
lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar
|
|
2
|
Deveraux QL and Reed JC: IAP family
proteins - suppressors of apoptosis. Genes Dev. 13:239–252. 1999.
View Article : Google Scholar
|
|
3
|
Miller LK: An exegesis of IAPs: Salvation
and surprises from BIR motifs. Trends Cell Biol. 9:323–328. 1999.
View Article : Google Scholar
|
|
4
|
Li F, Ambrosini G, Chu EY, Plescia J,
Tognin S, Marchisio PC and Altieri DC: Control of apoptosis and
mitotic spindle checkpoint by survivin. Nature. 396:580–584. 1998.
View Article : Google Scholar
|
|
5
|
Altieri DC and Marchisio PC: Survivin
apoptosis: An interloper between cell death and cell proliferation
in cancer. Lab Invest. 79:1327–1333. 1999.
|
|
6
|
Li F, Ackermann EJ, Bennett CF, Rothermel
AL, Plescia J, Tognin S, Villa A, Marchisio PC and Altieri DC:
Pleiotropic cell-division defects and apoptosis induced by
interference with survivin function. Nat Cell Biol. 1:461–466.
1999. View Article : Google Scholar
|
|
7
|
Chantalat L, Skoufias DA, Kleman JP, Jung
B, Dideberg O and Margolis RL: Crystal structure of human survivin
reveals a bow tie-shaped dimer with two unusual alpha-helical
extensions. Mol Cell. 6:183–189. 2000. View Article : Google Scholar
|
|
8
|
Mahotka C, Wenzel M, Springer E, Gabbert
HE and Gerharz CD: Survivin-deltaEx3 and survivin-2B: Two novel
splice variants of the apoptosis inhibitor survivin with different
antiapoptotic properties. Cancer Res. 59:6097–6102. 1999.
|
|
9
|
Badran A, Yoshida A, Ishikawa K, Goi T,
Yamaguchi A, Ueda T and Inuzuka M: Identification of a novel splice
variant of the human anti-apoptopsis gene survivin. Biochem Biophys
Res Commun. 314:902–907. 2004. View Article : Google Scholar
|
|
10
|
Caldas H, Honsey LE and Altura RA:
Survivin 2alpha: A novel Survivin splice variant expressed in human
malignancies. Mol Cancer. 4:112005. View Article : Google Scholar
|
|
11
|
Reed JC: The Survivin saga goes in vivo. J
Clin Invest. 108:965–969. 2001. View
Article : Google Scholar
|
|
12
|
Satoh K, Kaneko K, Hirota M, Masamune A,
Satoh A and Shimosegawa T: Expression of survivin is correlated
with cancer cell apoptosis and is involved in the development of
human pancreatic duct cell tumors. Cancer. 92:271–278. 2001.
View Article : Google Scholar
|
|
13
|
Tanaka C, Uzawa K, Shibahara T, Yokoe H,
Noma H and Tanzawa H: Expression of an inhibitor of apoptosis,
survivin, in oral carcinogenesis. J Dent Res. 82:607–611. 2003.
View Article : Google Scholar
|
|
14
|
Dallaglio K, Marconi A and Pincelli C:
Survivin: A dual player in healthy and diseased skin. J Invest
Dermatol. 132:18–27. 2012. View Article : Google Scholar
|
|
15
|
Dohi T, Beltrami E, Wall NR, Plescia J and
Altieri DC: Mitochondrial survivin inhibits apoptosis and promotes
tumorigenesis. J Clin Invest. 114:1117–1127. 2004. View Article : Google Scholar
|
|
16
|
Fortugno P, Wall NR, Giodini A, O'Connor
DS, Plescia J, Padgett KM, Tognin S, Marchisio PC and Altieri DC:
Survivin exists in immunochemically distinct subcellular pools and
is involved in spindle microtubule function. J Cell Sci.
115:575–585. 2002.
|
|
17
|
Dohi T, Okada K, Xia F, Wilford CE, Samuel
T, Welsh K, Marusawa H, Zou H, Armstrong R, Matsuzawa S, et al: An
IAP-IAP complex inhibits apoptosis. J Biol Chem. 279:34087–34090.
2004. View Article : Google Scholar
|
|
18
|
Khan S, Jutzy JM, Aspe JR, McGregor DW,
Neidigh JW and Wall NR: Survivin is released from cancer cells via
exosomes. Apoptosis. 16:1–12. 2011. View Article : Google Scholar
|
|
19
|
Wright ME, Han DK and Hockenbery DM:
Caspase-3 and inhibitor of apoptosis protein(s) interactions in
Saccharomyces cerevisiae and mammalian cells. FEBS Lett.
481:13–18. 2000. View Article : Google Scholar
|
|
20
|
Song Z, Yao X and Wu M: Direct interaction
between survivin and Smac/DIABLO is essential for the
anti-apoptotic activity of survivin during taxol-induced apoptosis.
J Biol Chem. 278:23130–23140. 2003. View Article : Google Scholar
|
|
21
|
Tamm I, Wang Y, Sausville E, Scudiero DA,
Vigna N, Oltersdorf T and Reed JC: IAP-family protein survivin
inhibits caspase activity and apoptosis induced by Fas (CD95), Bax,
caspases, and anticancer drugs. Cancer Res. 58:5315–5320. 1998.
|
|
22
|
Chen J, Wu W, Tahir SK, Kroeger PE,
Rosenberg SH, Cowsert LM, Bennett F, Krajewski S, Krajewska M,
Welsh K, et al: Down-regulation of survivin by antisense
oligonucleotides increases apoptosis, inhibits cytokinesis and
anchorage-independent growth. Neoplasia. 2:235–241. 2000.
View Article : Google Scholar
|
|
23
|
Olie RA, Simões-Wüst AP, Baumann B, Leech
SH, Fabbro D, Stahel RA and Zangemeister-Wittke U: A novel
antisense oligonucleotide targeting survivin expression induces
apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer
Res. 60:2805–2809. 2000.
|
|
24
|
Chandele A, Prasad V, Jagtap JC, Shukla R
and Shastry PR: Upregulation of survivin in G2/M cells and
inhibition of caspase 9 activity enhances resistance in
staurosporine-induced apoptosis. Neoplasia. 6:29–40. 2004.
View Article : Google Scholar
|
|
25
|
Suzuki A, Hayashida M, Ito T, Kawano H,
Nakano T, Miura M, Akahane K and Shiraki K: Survivin initiates cell
cycle entry by the competitive interaction with Cdk4/p16(INK4a) and
Cdk2/cyclin E complex activation. Oncogene. 19:3225–3234. 2000.
View Article : Google Scholar
|
|
26
|
Jeyaprakash AA, Klein UR, Lindner D, Ebert
J, Nigg EA and Conti E: Structure of a Survivin-Borealin-INCENP
core complex reveals how chromosomal passengers travel together.
Cell. 131:271–285. 2007. View Article : Google Scholar
|
|
27
|
D'Avino PP and Capalbo L: New Auroras on
the roles of the chromosomal passenger complex in cytokinesis:
Implications for cancer therapies. Front Oncol. 5:2212015.
|
|
28
|
Li Y, Liu D, Zhou Y, Li Y, Xie J, Lee RJ,
Cai Y and Teng L: Silencing of survivin expression leads to reduced
proliferation and cell cycle arrest in cancer cells. J Cancer.
6:1187–1194. 2015. View Article : Google Scholar
|
|
29
|
Hagenbuchner J, Kiechl-Kohlendorfer U,
Obexer P and Ausserlechner MJ: BIRC5/Survivin as a target for
glycolysis inhibition in high-stage neuroblastoma. Oncogene.
35:2052–2061. 2016. View Article : Google Scholar
|
|
30
|
Véquaud E, Séveno C, Loussouarn D,
Engelhart L, Campone M, Juin P and Barillé-Nion S: YM155 potently
triggers cell death in breast cancer cells through an
autophagy-NF-kB network. Oncotarget. 6:13476–13486. 2015.
View Article : Google Scholar
|
|
31
|
Ding YH, Fan XD, Wu JJ, Deng ZK, Wei B and
Li YF: Effect of YM155 on Apoptosis and Autophagy of K562 Cells.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 23:375–380. 2015.(In
Chinese).
|
|
32
|
Jiang G, Ren B, Xu L, Song S, Zhu C and Ye
F: Survivin may enhance DNA double-strand break repair capability
by up-regulating Ku70 in human KB cells. Anticancer Res.
29:223–228. 2009.
|
|
33
|
Véquaud E, Desplanques G, Jézéquel P, Juin
P and Barillé-Nion S: Survivin contributes to DNA repair by
homologous recombination in breast cancer cells. Breast Cancer Res
Treat. 155:53–63. 2016. View Article : Google Scholar
|
|
34
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar
|
|
35
|
Jia X, Gao Y, Zhai D, Liu J, Wang Y, Jing
LI and Du Z: Survivin is not a promising serological maker for the
diagnosis of hepatocellular carcinoma. Oncol Lett. 9:2347–2352.
2015. View Article : Google Scholar
|
|
36
|
You WANG, Qing-yun ZHANG, Ya-ming WANG and
Jian-jun XU: Cloning of survivin gene and preparation its
monoclonoal antibodies as well as checking survivin expression in
liver carcinoma cells. Clin J Lab Med. 29:258–262. 2006.
|
|
37
|
Li X, Wang Y, Xu J and Zhang Q: Sandwich
ELISA for detecting urinary Survivin in bladder cancer. Chin J
Cancer Res. 25:375–381. 2013.
|
|
38
|
Liu C, Guo J, Qu L, Bing D, Meng L, Wu J
and Shou C: Applications of novel monoclonal antibodies specific
for synuclein-gamma in evaluating its levels in sera and cancer
tissues from colorectal cancer patients. Cancer Lett. 269:148–158.
2008. View Article : Google Scholar
|
|
39
|
Jamshidian H, Kor K and Djalali M: Urine
concentration of nuclear matrix protein 22 for diagnosis of
transitional cell carcinoma of bladder. Urol J. 5:243–247.
2008.
|
|
40
|
Önal B, Han Ü, Yilmaz S, Köybasioglu F and
Altuğ U: The use of urinary nuclear matrix protein 22 (NMP22) as a
diagnostic adjunct to urine cytology for monitoring of recurrent
bladder cancer-institutional experience and review. Diagn
Cytopathol. 43:307–314. 2015. View
Article : Google Scholar
|
|
41
|
Sah NK and Seniya C: Survivin splice
variants and their diagnostic significance. Tumour Biol.
36:6623–6631. 2015. View Article : Google Scholar
|
|
42
|
Srivastava AK, Singh PK, Srivastava K,
Singh D, Dalela D, Rath SK, Goel MM and Bhatt Brahma ML: Diagnostic
role of survivin in urinary bladder cancer. Asian Pac J Cancer
Prev. 14:81–85. 2013. View Article : Google Scholar
|
|
43
|
Eissa S, Swellam M, Shehata H, El-Khouly
IM, El-Zayat T and El-Ahmady O: Expression of HYAL1 and survivin
RNA as diagnostic molecular markers for bladder cancer. J Urol.
183:493–498. 2010. View Article : Google Scholar
|
|
44
|
Plewka D, Jakubiec-Bartnik B, Morek M,
Bogunia E, Bienioszek M, Wolski H, Kotrych D, Dziekan K,
Seremak-Mrozikiewicz A and Plewka A: Survivin in ovary tumors.
Ginekol Pol. 86:525–530. 2015. View Article : Google Scholar
|
|
45
|
Zhang Y, Wang J, Sui X, Li Y, Lu K, Fang
X, Jiang Y and Wang X: Prognostic and clinicopathological value of
survivin in diffuse large B-cell lymphoma: A meta-analysis.
Medicine (Baltimore). 94:e14322015. View Article : Google Scholar
|
|
46
|
Akhtar M, Gallagher L and Rohan S:
Survivin: Role in diagnosis, prognosis, and treatment of bladder
cancer. Adv Anat Pathol. 13:122–126. 2006. View Article : Google Scholar
|
|
47
|
Goričar K, Kovač V, Franko A, Dodič-Fikfak
M and Dolžan V: Serum survivin levels and outcome of chemotherapy
in patients with malignant mesothelioma. Dis Markers.
2015:3167392015. View Article : Google Scholar
|
|
48
|
Yu CJ, Ou JH, Wang ML, Jialielihan N and
Liu YH: Elevated survivin mediated multidrug resistance and reduced
apoptosis in breast cancer stem cells. J BUON. 20:1287–1294.
2015.
|
|
49
|
Lee MR, Ji SY, Mia-Jan K and Cho MY:
Chemoresistance of CD133(+) colon cancer may be related with
increased survivin expression. Biochem Biophys Res Commun.
463:229–234. 2015. View Article : Google Scholar
|
|
50
|
Cheng Q, Ling X, Haller A, Nakahara T,
Yamanaka K, Kita A, Koutoku H, Takeuchi M, Brattain MG and Li F:
Suppression of survivin promoter activity by YM155 involves
disruption of Sp1-DNA interaction in the survivin core promoter.
Int J Biochem Mol Biol. 3:179–197. 2012.
|
|
51
|
Kudchadkar R, Ernst S, Chmielowski B,
Redman BG, Steinberg J, Keating A, Jie F, Chen C, Gonzalez R and
Weber J: A phase 2, multicenter, open-label study of sepantronium
bromide (YM155) plus docetaxel in patients with stage III
(unresectable) or stage IV melanoma. Cancer Med. 4:643–650. 2015.
View Article : Google Scholar
|
|
52
|
Carrasco RA, Stamm NB, Marcusson E,
Sandusky G, Iversen P and Patel BK: Antisense inhibition of
survivin expression as a cancer therapeutic. Mol Cancer Ther.
10:221–232. 2011. View Article : Google Scholar
|
|
53
|
Hansen JB, Fisker N, Westergaard M,
Kjaerulff LS, Hansen HF, Thrue CA, Rosenbohm C, Wissenbach M, Orum
H and Koch T: SPC3042: A proapoptotic survivin inhibitor. Mol
Cancer Ther. 7:2736–2745. 2008. View Article : Google Scholar
|
|
54
|
Coumar MS, Tsai FY, Kanwar JR, Sarvagalla
S and Cheung CH: Treat cancers by targeting survivin: Just a dream
or future reality? Cancer Treat Rev. 39:802–811. 2013. View Article : Google Scholar
|
|
55
|
Li F: Survivin study: What is the next
wave? J Cell Physiol. 197:8–29. 2003. View Article : Google Scholar
|
|
56
|
Zeng W, Li H, Chen Y, Lv H, Liu L, Ran J,
Sun X, Bieerkehazhi S, Liu Y, Li X, et al: Survivin activates NF-κB
p65 via the IKKβ promoter in esophageal squamous cell carcinoma.
Mol Med Rep. 13:1869–1880. 2016. View Article : Google Scholar
|
|
57
|
Kim JS, Kim HA, Seong MK, Seol H, Oh JS,
Kim EK, Chang JW, Hwang SG and Noh WC: STAT3-survivin signaling
mediates a poor response to radiotherapy in HER2-positive breast
cancers. Oncotarget. 7:7055–7065. 2016.
|
|
58
|
Johnson DC, Greene PS and Nielsen ME:
Surgical advances in bladder cancer: At what cost? Urol Clin North
Am. 42:235–252, ix. 2015.ix. View Article : Google Scholar
|
|
59
|
Macleod LC, Hotaling JM, Wright JL,
Davenport MT, Gore JL, Harper J and White E: Risk factors for renal
cell carcinoma in the VITAL study. J Urol. 190:1657–1661. 2013.
View Article : Google Scholar
|
|
60
|
Setiawan VW, Stram DO, Nomura AM, Kolonel
LN and Henderson BE: Risk factors for renal cell cancer: The
multiethnic cohort. Am J Epidemiol. 166:932–940. 2007. View Article : Google Scholar
|
|
61
|
Antonacopoulou AG, Floratou K, Bravou V,
Kottorou A, Dimitrakopoulos FI, Marousi S, Stavropoulos M, Koutras
AK, Scopa CD and Kalofonos HP: The survivin −31 snp in human
colorectal cancer correlates with survivin splice variant
expression and improved overall survival. Anal Cell Pathol (Amst).
33:177–189. 2010. View Article : Google Scholar
|
|
62
|
Ge QX, Li YY, Nie YQ, Zuo WG and Du YL:
Expression of survivin and its four splice variants in colorectal
cancer and its clinical significances. Med Oncol. 30:5352013.
View Article : Google Scholar
|
|
63
|
Muchmore SW, Chen J, Jakob C, Zakula D,
Matayoshi ED, Wu W, Zhang H, Li F, Ng SC and Altieri DC: Crystal
structure and mutagenic analysis of the inhibitor-of-apoptosis
protein survivin. Mol Cell. 6:173–182. 2000. View Article : Google Scholar
|
|
64
|
Caldas H, Jiang Y, Holloway MP, Fangusaro
J, Mahotka C, Conway EM and Altura RA: Survivin splice variants
regulate the balance between proliferation and cell death.
Oncogene. 24:1994–2007. 2005. View Article : Google Scholar
|
|
65
|
Necochea-Campion R, Chen CS, Mirshahidi S,
Howard FD and Wall NR: Clinico-pathologic relevance of Survivin
splice variant expression in cancer. Cancer Lett. 339:167–174.
2013. View Article : Google Scholar
|
|
66
|
Li F, Yang J, Ramnath N, Javle MM and Tan
D: Nuclear or cytoplasmic expression of survivin: What is the
significance? Int J Cancer. 114:509–512. 2005. View Article : Google Scholar
|
|
67
|
Piras F, Murtas D, Minerba L, Ugalde J,
Floris C, Maxia C, Colombari R, Perra MT and Sirigu P: Nuclear
survivin is associated with disease recurrence and poor survival in
patients with cutaneous malignant melanoma. Histopathology.
50:835–842. 2007. View Article : Google Scholar
|
|
68
|
Hou Y, Hu Q, Liu AG, Zhang LQ and Liu SY:
Expression of survivin and its location in bone marrow cells of
childhood acute leukemia: Relationship to therapeutic efficacy.
Zhongguo Dang Dai Er Ke Za Zhi. 8:101–104. 2006.(In Chinese).
|
|
69
|
Takasu C, Shimada M, Kurita N, Iwata T,
Sato H, Nishioka M, Morimoto S, Yoshikawa K, Miyatani T, Kashihara
H, et al: Survivin expression can predict the effect of
chemoradiotherapy for advanced lower rectal cancer. Int J Clin
Oncol. 18:869–876. 2013. View Article : Google Scholar
|
